Viread Articles
Gilead 1st-qtr 2004 revenues rocket 87%
3 May 2004
Japan Tobacco and Torii introduce new HIV drug in Japan
19 April 2004
Viread/Emtriva tablet filed in USA and EU
22 March 2004
Preliminary data from three-year Viread trial
16 February 2004
Stock Commentary - New York
9 February 2004
Stock Commentary - New York
10 November 2003
Gilead soars on strong HIV drug sales
10 November 2003
Gilead's Emtriva wins EU approval
3 November 2003
Gilead starts Viread/Emtriva combi study
18 August 2003
Gilead signs deal with Japan Tobacco
11 August 2003
Gilead's Emtriva on track for EU approval
4 August 2003
Stock Commentary - New York
21 July 2003
Gilead Sciences set to beat expectations
21 July 2003
Gilead's Viread gains expanded use in EU
2 June 2003
Gilead offers cuts-price Viread to LDCs
14 April 2003
Gilead predicts good Viread sales in 2003
24 March 2003
Gilead's Hepsera for hep B OKed in Europe
17 March 2003
Positive Ph III data with Triangle's emtricitabine
17 February 2003
Stock Commentary - New York
10 February 2003
Sales rocket at Gilead on Viread growth
10 February 2003
Gilead cuts HIV/AIDS drug price for Africa
6 January 2003
Stock Commentary - New York
20 May 2002
Viread suppresses HIV viral load at 48 weeks
11 March 2002
Gilead gets EU OK for HIV drug Viread
18 February 2002
Healthy revenue growth at Gilead
11 February 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
OSI acquires oncology assets from Gilead in $200 million deal
27 November 2001
Glead's Viread for HIV set for launch in USA "within days"
29 October 2001
Update: CPMP backs Gilead's Viread for HIV
24 October 2001
EMEA committee recommends approval of Gilead's Viread
19 October 2001
Stock Commentary - New York
30 August 2001
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
